Jordan D. Berlin, MD, Ingram Professor of Cancer Research and Clinical Director of the GI Oncology Program at Vanderbilt-Ingram Cancer Center, Nashville, commented on the findings of TRIBE.
“This study is outstanding, and while we don’t have overall survival data yet the findings suggest that we can very well use FOLFOXIRI with bevacizumab,” Dr. Berlin said. “Particularly interesting though not surprising is the finding that throwing all the drugs into the mix at once does increase the response rate. We therefore hope that this regimen would be useful prior to hepatic resection, to increase the possibility of resection for patients who are not quite there yet. While the findings do not yet change the standard of care, they give us more leeway in how we look at these patients and more options for individualizing their treatment.” ■
Disclosure: Dr. Berlin reported no potential conflicts of interest.
For the treatment of metastatic colorectal cancer, better outcomes were achieved when bevacizumab (Avastin) was added to FOLFOXIRI (leucovorin, fluorouracil [5-FU], oxaliplatin, irinotecan), rather than FOLFIRI (leucovorin, 5-FU, irinotecan), in the phase III TRIBE trial conducted at 35 Italian...